NSABP FC-10
NSABP FC-10
A Phase IB Study of Pembolizumab in Combination with Pemetrexed and Oxaliplatin in Subjects with Chemo-refractory Metastatic Colorectal Cancer
Protocol Chair: Shannon Puhalla, MD
Protocol Officer: Thomas George, MD
Patient Population:
Patients with metastatic colorectal cancer refractory to chemotherapy
Target Accrual: 33 patients
Status: Active, Not Recruiting
ClinicialTrials.gov Identifier: NCT03626922
A Phase IB Study of Pembolizumab in Combination with Pemetrexed and Oxaliplatin in Subjects with Chemo-refractory Metastatic Colorectal Cancer
Protocol Chair: Shannon Puhalla, MD
Protocol Officer: Thomas George, MD
Patient Population:
Patients with metastatic colorectal cancer refractory to chemotherapy
Target Accrual: 33 patients
Status: Active, Not Recruiting
ClinicialTrials.gov Identifier: NCT03626922